Philip Morris International Aktie

https://www.wallstreet-online.de/nachricht/20053981-philip-morris-international-reports-2025-third-quarter-first-nine-months-results PHILIP MORRIS - Rauchfreie Produkte treiben das Wachstum an Philip Morris International (PMI) hat im dritten Quartal 2025 den Gewinn deutlich ausgebaut und die Jahresziele leicht angehoben. Der bereinigte Gewinn je Aktie stieg um 17,3 % auf 2,24 USD und übertraf damit die Analystenschätzungen von 2,11 USD. Der Umsatz erhöhte sich um 9,4 % auf 10,85 Mrd. USD, organisch um 5,9 %. Der nach US-GAAP ausgewiesene Gewinn je Aktie legte um 13,2 % auf 2,23 USD zu. Für das Gesamtjahr erwartet der Konzern nun ein bereinigtes Ergebnis pro Aktie zwischen 7,46 USD und 7,56 USD nach zuvor 7,43 USD bis 7,56 USD. Das entspräche einem Plus von bis zu 15,1 % gegenüber dem Vorjahr. Das organische Umsatzwachstum soll weiterhin rund 8 % betragen. weiter hier: https://stock3.com/news/philip-morris-rauchfreie-produkte-treiben-das-wachstum-an-16730406

Es sind viele zittrige Hände in Markt. Erst +5%, dann -8% ... kann gerne unter 90€ korrigieren dann kaufe ich weiter zu

Sah heute Vormittag noch gut aus

https://www.investing.com/news/stock-market-news/philip-morriss-revenue-misses-estimates-as-cigarette-volumes-drop-4145925 https://www.wallstreet-online.de/nachricht/19661718-philip-morris-international-reports-2025-second-quarter-first-six-months-results-and-raises-full-year-guidance-second-quarter-reported-diluted-eps-grew-26-6-to-1-95-adjusted-diluted-eps-grew-20-1-to-1-91-and-by-18-9-excluding-currency Results Highlights - Second Quarter 2025 Smoke-free business (SFB): Our smoke-free business accounted for 41% of total net revenues (up by 2.9pp vs. Q2 last year) and over 42% of total gross profit (up by 3.8pp vs. Q2 last year). Our smoke-free products are now available in 97 markets, nearly half of which have at least two of our three flagship brands (IQOS, ZYN and VEEV) available for sale, including 20 markets with all three. Our SFB continues to deliver superior performance, with shipment volumes up by 11.8%, net revenues growing by 15.2% (14.5% organically) and gross profit increasing by 23.3% (21.5% organically). Inhalable smoke-free products (SFP): Our international smoke-free portfolio is centered on IQOS, which exceeded 3 billion dollars in quarterly net revenues. It continues to strengthen its overall position as the second largest nicotine ‘brand’ in markets where present (gaining 1.0pp of combined cigarette and HTU industry volumes to reach 9.2% share) and is driving the growth of the global heat-not-burn category, where PMI holds approximately 76% volume share. HTU adjusted in-market sales (IMS) volume, which excludes the net impact of estimated distributor and wholesaler inventory movements, reaccelerated back to double-digit growth of 11.4%, driven by our commercial initiatives, and notable improvement in Europe as the impact of the characterizing flavor ban subsides in affected markets. In Japan, IQOS reached over 10 million legal-age consumers. IQOS HTU adjusted market share increased by 2.3pp to 31.7% with both TEREA and SENTIA further strengthening their #1 and #3 positions, notwithstanding increased competitive intensity. Adjusted IMS grew by an estimated 7.8% against a strong prior year comparator, which included the introduction of ILUMA i. In Europe, adjusted IMS growth reaccelerated to an estimated 9.1%, with Italy a notable strong performer as well as impressive broad-based growth across markets including Germany, Greece, Romania, Bulgaria and Spain. This was fueled by the continued roll-out of ILUMA i and expansion of the consumables portfolio, including the further roll-out of DELIA and new variants of tobacco-free LEVIA. IQOS HTU adjusted market share increased by 1.2pp to 10.9%, with offtake share exceeding 20% in key cities of 12 markets. Outside Europe and Japan, strong adjusted IMS growth continued and offtake share increased in key cities across the globe, including Jakarta, Mexico City, Tunis, Riyadh, Kuala Lumpur, and Seoul. Following promising results of the BONDS by IQOS pilot, a broader roll-out in Indonesia has commenced in the latter half of the quarter. In the e-vapor category, VEEV continued its increasingly profitable growth, and is now available in 42 markets. Shipment volumes more than doubled, driven by Europe. Within the closed pods segment, VEEV holds the #1 position in 6 European markets, including Greece and Italy. PMI remains committed to building and commercializing the brand in a focused, responsible and profitable manner, as illustrated by the recently launched innovation VEEV inPrime, which offers superior consumer experience and an optimized pod cost. Oral SFP: Shipment volume increased by 23.8% in pouch or pouch equivalents (26.5% in cans), fueled by nicotine pouches, which more than doubled outside the U.S. and Nordics, and in the U.S. grew by over 40% to 190 million cans. In the U.S., ZYN reaccelerated its offtake growth to approximately 36% in June, and 26% in Q2 overall as measured by Nielsen. This reflects the strength of the brand as in-store availability improved and legal-age consumers regain access to the full ZYN portfolio offering. Restocking was effectively completed in the first-half, with the estimated impact slightly lower than initially expected. To further grow the brand and nicotine pouch category overall, commercial activities were reaccelerated towards the end of the quarter. The growth of the international nicotine pouch business was fueled by strong offtake and geographic expansion. The category is nascent in the majority of markets and our focus is on switching legal-age smokers with a relevant product portfolio. Global Travel Retail, Pakistan, the UK, South Africa, Mexico and Poland delivered strong performances. Following further launches, ZYN is now available in 44 markets. Combustibles: Notwithstanding the expected return to volume declines, net revenues grew by 2.1% (up 2.0% organically) fueled by strong pricing, partly offset by negative mix dynamics. This drove another quarter of robust gross profit growth of 5.0% (4.8% organically). Marlboro continues to gain market share, achieving its highest quarterly market share since the 2008 spin. Our overall cigarette category share was broadly stable. Dividend: Declared regular quarterly dividend of $1.35 per share, or an annualized $5.40 per share.